GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyax Corp (NAS:DYAX) » Definitions » EBITDA

Dyax (DYAX) EBITDA : $-17.14 Mil (TTM As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is Dyax EBITDA?

Dyax's EBITDA for the three months ended in Sep. 2015 was $-8.01 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Sep. 2015 was $-17.14 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Dyax's EBITDA per Share for the three months ended in Sep. 2015 was $-0.06. Its EBITDA per share for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.12.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


Dyax EBITDA Historical Data

The historical data trend for Dyax's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyax EBITDA Chart

Dyax Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.73 -23.49 -17.71 -16.12 -0.09

Dyax Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.16 0.65 -4.33 -5.45 -8.01

Competitive Comparison of Dyax's EBITDA

For the Biotechnology subindustry, Dyax's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dyax's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyax's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dyax's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Dyax's EBITDA for the fiscal year that ended in Dec. 2014 is calculated as

Dyax's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2014, Dyax's EBITDA was $-0.09 Mil.

Dyax's EBITDA for the quarter that ended in Sep. 2015 is calculated as

Dyax's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Sep. 2015, Dyax's EBITDA was $-8.01 Mil.

EBITDA for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Dyax  (NAS:DYAX) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Dyax EBITDA Related Terms

Thank you for viewing the detailed overview of Dyax's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Dyax (DYAX) Business Description

Traded in Other Exchanges
N/A
Address
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
Executives
David J Mclachlan other: Former director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Gustav Christensen officer: CEO and President, other: Former director DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Todd Bazemore officer: EVP & Chief Commercial Officer C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Thomas L Kempner other: Former director C/O LOEB PARTNERS CORPORATION, 125 BROAD STREET, 14TH FLOOR, NEW YORK NY 10004
Abbie Celniker other: Former director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Marc D Kozin other: Former director
Andrew D. Ashe officer: General Counsel & EVP C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ron Cohen other: Former director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Mary Ann Gray other: Former director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
George V Migausky officer: EVP & Chief Financial Officer C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Pucci other: Former director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Burt A Adelman officer: CMO & EVP, R&D DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ivana Magovcevic-liebisch officer: EVP; Chief Operating Officer 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Susan B Bayh director WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Stephen S Galliker officer: EVP and CFO 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139

Dyax (DYAX) Headlines

From GuruFocus

Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 03-15-2011

Mario Gabelli Comments on Dyax Corp

By Holly LaFon Holly LaFon 01-29-2016

Chuck Royce Makes Big Gains on Divestitures

By Samira Meskini Samira Meskini 01-03-2016

Mario Gabelli Comments on Dyax Corp

By Holly LaFon Holly LaFon 05-03-2016

Dyax Corp. (DYAX) CEO Gustav Christensen buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 09-15-2010

Meridian Funds Comments on Dyax Corp

By Holly LaFon Holly LaFon 03-07-2016

Dyax Corp. Reports Operating Results (10-Q)

By gurufocus 10qk 11-02-2010